EPISODE · Apr 2, 2025 · 10 MIN
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
from BiotechTV - News · host BiotechTV
CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.
Embed this episode
NOW PLAYING
BioTrinity 2025: With a novel E3 ubiquitin ligase (TRIM21) for protein degradation, Cambridge, UK based TRIMTECH Therapeutics recently raised a $31 million seed round
0:00
10:41
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 10 minutes long.
When was this BiotechTV - News episode published?
This episode was published on April 2, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!